Duo Oncology Secures U.S. Composition of Matter Patent for Platform Chemistry and Lead Product.
Strengthening Intellectual Property Portfolio for Duo Oncology’s Pipeline of First-in-Class Dual-Action Anti-Cancer Therapies
PITTSBURGH (PRWEB) February 13, 2025 – Duo Oncology, a clinic-ready biotechnology company developing replacements for foundational chemotherapies, today announced the issuance of a U.S. composition of matter patent for the chemistry of its prodrug nanomedicine platform. The patent, granted by the United States Patent and Trademark Office (USPTO), significantly bolsters intellectual property protection in the U.S. market for Duo’s dual-modality nanomedicines, including lead product DUO-207.
DUO-207 is a novel, first-in-class nanomedicine co-delivering gemcitabine and paclitaxel formulated as an ultrasmall nanomedicine capable of penetrating dense tumor stroma. DUO-207 has demonstrated promising preclinical efficacy in numerous preclinical tumor models and a better safety profile than standard of care in GLP toxicology studies. DUO-207 is currently advancing to Phase I clinical trials expected to begin in mid-2025.
“Securing this U.S. composition of matter patent is a critical milestone for Duo Oncology, protecting the unique chemical structure of our ultrasmall prodrug nanomedicines,” said Sam Rothstein, CEO of Duo Oncology. “This patent not only safeguards our pipeline but also enhances the commercial potential of DUO-207 as we move closer to delivering transformative treatments for patients.”
The newly granted patent extends protection for DUO-207 and other pipeline products in the U.S. through 2040, complementing existing international patent applications and pending approvals in key global markets.
